PURE Bioscience, Inc. (OTCMKTS:PURE – Get Free Report) was the recipient of a significant drop in short interest in August. As of August 31st, there was short interest totalling 19,700 shares, a drop of 36.9% from the August 15th total of 31,200 shares. Based on an average trading volume of 54,100 shares, the days-to-cover ratio is currently 0.4 days.
PURE Bioscience Price Performance
Shares of PURE opened at $0.11 on Friday. The firm’s 50 day moving average price is $0.10 and its 200 day moving average price is $0.11. PURE Bioscience has a twelve month low of $0.07 and a twelve month high of $0.23.
PURE Bioscience (OTCMKTS:PURE – Get Free Report) last announced its quarterly earnings results on Wednesday, June 14th. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.41 million for the quarter. PURE Bioscience had a negative net margin of 247.89% and a negative return on equity of 151.03%.
PURE Bioscience Company Profile
PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.
- Five stocks we like better than PURE Bioscience
- How to Calculate Options Profits
- 2 Wrecked Stocks Keeping Cars on the Road Ready for Repair
- Utilities Stocks Explained – How and Why to Invest in Utilities
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- Why Consider Investing in Nanotechnology Stocks
- Shutterstock is the Value Stock they don’t want you to know about
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.